Nav: Home

Repeat vaccination is safe for most kids with mild to moderate reactions

September 14, 2018

September 14, 2018 - Children who experience some type of adverse event following initial immunization have a low rate of recurrent reactions to subsequent vaccinations, reports a study in The Pediatric Infectious Disease Journal, the official journal of The European Society for Paediatric Infectious Diseases. The journal is published in the Lippincott portfolio by Wolters Kluwer.

"Most patients with a history of mild or moderate adverse events following immunization [AEFI] can be safely reimmunized," write Gaston De Serres, MD, of Laval University, Quebec, and colleagues. Although recurrent AEFIs can sometimes occur after repeat doses of vaccine, this study suggests that the risk of recurrent AEFIs after re-vaccination is relatively low, especially when the previous reaction was mild or moderate.

Safety of Repeat Vaccination after Initial Reactions - 'Passive Surveillance' Data In Quebec, healthcare professionals are legally required to report any "unusual or severe" AEFI related to a "passive surveillance" system similar to the Vaccine Adverse Event Reporting System (VAERS) used in the United States. The analysis included 5,600 patients with AEFIs reported to Quebec's passive surveillance database from 1998 through 2016, all of whom required further doses of the vaccine to which they reacted. (The analysis excluded seasonal influenza vaccine, which changes from year to year.)

Of 1,731 patients with available follow-up data, 1,350 patients were re-vaccinated: a rate of 78 percent. Most of the re-vaccinated children were under two years old; about one-half of the AEFIs were allergic-like reactions.

Sixteen percent of patients experienced some type of recurrent AEFI after re-vaccination. In more than 80 percent of cases, the recurrent reaction was no more severe than the initial reaction. The researchers analyzed potential risk factors for recurrent reactions, including:

  • Patient Characteristics. Children under age 2 were more likely to be re-vaccinated and less likely to have recurrent reactions, compared to older patients. Recurrence risk was similar for males and females.
  • Type of AEFI. Recurrence rate was similar for patients with most types of initial AEFIs. The risk was highest (67 percent) for patients with large local reactions with "extensive limb swelling." For patients who had allergic-type reactions, the recurrence rate was 12 percent. Severe allergic events (anaphylaxis) were very rare after re-vaccination.
  • Severity of AEFI. Patients with more severe initial AEFIs were less likely to be re-vaccinated: only 60 percent of children with severe reactions were re-vaccinated, compared to 80 percent of those with less-severe reactions. Within this selected group, patients with severe AEFIs were less likely to have recurrences: eight versus 17 percent.
  • Type of Vaccine. The recurrence rate did not differ significantly for different types of vaccines. The re-vaccination rate was highest (90 percent) for children with AEFIs to diphtheria-tetanus-pertussis vaccines.
Prior to this study, there have been limited data on the safety of reimmunizing patients who had a prior AEFI. The study is one of the largest to estimate the rate of recurrent AEFIs by type of reaction and type of vaccine - key information for healthcare providers and parents/caregivers making decisions about further immunization. The results support the safety of continued vaccination especially when the previous reaction was mild or moderate.

The study provides helpful information on the risk of recurrent reactions to specific vaccines and in patients with different types of initial reactions. Dr. De Serres and coauthors suggest that vaccine adverse event passive surveillance systems could be adapted to include "systematic and standardized follow-up" to provide more complete information on recurrence risk and other outcomes for children with AEFIs .
-end-
Click to read "Rate of Recurrence of Adverse Events Following Immunization: Results of 19 Years of Surveillance Ii Quebec, Canada"

DOI: 10.1097/INF.0000000000002162

About The Pediatric Infectious Disease Journal

The Pediatric Infectious Disease Journal®(PIDJ) is a complete, up-to-the-minute resource on infectious diseases in children. Through a mix of original studies, informative review articles, and unique case reports, PIDJ delivers the latest insights on combating disease in children -- from state-of-the-art diagnostic techniques to the most effective drug therapies and other treatment protocols. It is a resource that can improve patient care and stimulate your personal research. The Pediatric Infectious Disease Journal is the official journal of the European Society for Paediatric Infectious Diseases

About The European Society for Paediatric Infectious Diseases

Now in its 36th year, The European Society for Paediatric Infectious Diseases (ESPID) forms the basis for European investigators interested in infectious diseases in children and infection prevention in childhood. The society is engaged in a number of activities including the organisation of multicentre trials, international exchange of infectious disease fellows, and an annual meeting. Membership includes subscription to The Pediatric Infectious Disease Journal® in addition to many other benefits.

About Wolters Kluwer

Wolters Kluwer is a global leader in professional information, software solutions, and services for the health, tax & accounting, finance, risk & compliance, and legal sectors. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with specialized technology and services.

Wolters Kluwer, headquartered in the Netherlands, reported 2017 annual revenues of €4.4 billion. The company serves customers in over 180 countries, maintains operations in over 40 countries, and employs approximately 19,000 people worldwide.

Wolters Kluwer Health is a leading global provider of trusted clinical technology and evidence-based solutions that engage clinicians, patients, researchers and students with advanced clinical decision support, learning and research and clinical intelligence. For more information about our solutions, visit http://healthclarity.wolterskluwer.com and follow us on LinkedIn and Twitter @WKHealth.

Wolters Kluwer Health

Related Vaccines Articles:

Understanding T cell activation could lead to new vaccines
Scientists could be one step closer to developing vaccines against viruses such as Zika, West Nile or HIV, according to Penn State College of Medicine researchers.
Vaccines do work for pandemic flu, says study
Vaccines are successful in preventing pandemic flu and reducing the number of patients hospitalized as a result of the illness, a study led by academics at the University of Nottingham has found.
Research could lead to better vaccines and new antivirals
Scientists at Sanford Burnham Prebys Medical Discovery Institute (SBP) have identified a new regulator of the innate immune response -- the immediate, natural immune response to foreign invaders.
Toward opioid vaccines that can help prevent overdose fatalities
In 2014, the number of deaths from opioid overdoses in the US jumped to its highest level on record.
New, more effective strategy for producing flu vaccines
A team of researchers led by Yoshihiro Kawaoka, professor of pathobiological sciences at the University of Wisconsin-Madison School of Veterinary Medicine, has developed technology that could improve the production of vaccines that protect people from influenza B.
A method for storing vaccines at room temperature
Several simple and inexpensive techniques make it possible to store antiviral-vaccines at room temperature for several months.
Engineers design programmable RNA vaccines
MIT engineers have designed programmable RNA vaccines that could be rapidly manufactured and deployed.
Zika vaccines protect mice from infection
A single dose of either of two experimental Zika vaccines fully protected mice challenged with Zika virus four or eight weeks after receiving the inoculations.
Can we hypercharge vaccines?
Researchers at Boston Children's Hospital report that a fatty chemical naturally found in damaged tissues can induce an unexpected kind of immune response, causing immune cells to go into a 'hyperactive' state that is highly effective at rallying infection-fighting T-cells.
Vaccines: Don't leave home without them
While Americans should be fully vaccinated before travelling internationally to avoid infection with highly contagious diseases such as measles and hepatitis A, many are not, suggest two studies being presented at IDWeek 2015™.

Related Vaccines Reading:

Miller's Review of Critical Vaccine Studies: 400 Important Scientific Papers Summarized for Parents and Researchers
by Neil Z. Miller (Author)

The Vaccine-Friendly Plan: Dr. Paul's Safe and Effective Approach to Immunity and Health-from Pregnancy Through Your Child's Teen Years
by Paul Thomas M.D. (Author), Jennifer Margulis (Author)

Dissolving Illusions: Disease, Vaccines, and The Forgotten History
by Suzanne Humphries MD (Author), Roman Bystrianyk (Author)

The Vaccine Book: Making the Right Decision for Your Child (Sears Parenting Library)
by Robert W. Sears (Author)

Vaccines: A Reappraisal
by Richard Moskowitz MD (Author), Mary Holland (Foreword)

Vaccines, Autoimmunity, and the Changing Nature of Childhood Illness
by Dr. Thomas Cowan MD (Author), Sally Fallon Morell (Foreword)

Plotkin's Vaccines
by Stanley A. Plotkin MD (Author), Walter Orenstein MD DSc (HON) (Author), Paul A. Offit MD (Author), Kathryn M. Edwards MD (Author)

Vaccine Epidemic: How Corporate Greed, Biased Science, and Coercive Government Threaten Our Human Rights, Our Health, and Our Children
by Louise Kuo Habakus (Editor), Mary Holland (Editor), Kim Mack Rosenberg (Editor)

Vaccines and Autoimmunity
by Yehuda Shoenfeld (Editor), Nancy Agmon-Levin (Editor), Lucija Tomljenovic (Editor)

The HPV Vaccine On Trial: Seeking Justice for a Generation Betrayed
by Mary Holland (Author), Kim Mack Rosenberg (Author), Eileen Iorio (Author)

Best Science Podcasts 2018

We have hand picked the best science podcasts for 2018. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Dying Well
Is there a way to talk about death candidly, without fear ... and even with humor? How can we best prepare for it with those we love? This hour, TED speakers explore the beauty of life ... and death. Guests include lawyer Jason Rosenthal, humorist Emily Levine, banker and travel blogger Michelle Knox, mortician Caitlin Doughty, and entrepreneur Lux Narayan.
Now Playing: Science for the People

#492 Flint Water Crisis
This week we dig into the Flint water crisis: what happened, how it got so bad, what turned the tide, what's still left to do, and the mix of science, politics, and activism that are still needed to finish pulling Flint out of the crisis. We spend the hour with Dr Mona Hanna-Attisha, a physician, scientist, activist, the founder and director of the Pediatric Public Health Initiative, and author of the book "What the Eyes Don't See: A Story of Crisis, Resistance, and Hope in an American City".